Neil Kirby, Ph.D.
Dr. Kirby is an entrepreneur and chief executive with 30 years of experience leading biotechnology companies including Biogen, Genetics Institute (Wyeth), Vertex, TKT (Shire) and Stromedix. He also currently serves as president and CEO of Phoenix Tissue Repair, a company developing an innovative treatment for the rare disease dystrophic epidermolysis bullosa. Dr. Kirby is a board member of Edimer Pharmaceuticals, where he pioneered antenatal therapy for a rare developmental disorder known as XLHED (X-linked hypohidrotic ectodermal dysplasia). In addition, Dr. Kirby is chairman of Orphan Technologies, which is developing first-in-class therapeutics for rare diseases. Throughout his career, Dr. Kirby has held positions of increasing responsibility in global regulatory affairs, strategic planning, portfolio management, non-clinical development, manufacturing and program management. He’s also been involved with the development, registration and successful commercial launches of life-saving biopharmaceuticals including recombinant coagulation factors, cytokines and enzyme replacement therapies. Dr. Kirby received his Ph.D. in the faculty of medicine from the University of London in the U.K.